### Table S1. Distribution of symptoms experience by transplant recipients with COVID-19.

| Symptom                  | All patients, n (%) | No oxygen requirement (n = 91), n (%) | Oxygen requirement (n = 69), n (%) |
|--------------------------|---------------------|--------------------------------------|-----------------------------------|
| Fever (n = 146)          | 82 (56.0)           | 48 (52.7)                            | 34 (49.3)                         |
| Sore throat (n = 135)    | 29 (21.5)           | 20 (22.0)                            | 9 (13.0)                          |
| Cough (n = 142)          | 84 (59.2)           | 51 (56.0)                            | 33 (47.8)                         |
| Myalgia (n = 135)        | 50 (37.0)           | 31 (34.1)                            | 19 (27.5)                         |
| Dyspnea (n = 154)        | 78 (50.6)           | 23 (25.3)                            | 55 (79.7)                         |
| Headache (n = 135)       | 34 (25.2)           | 25 (27.5)                            | 9 (13.0)                          |
| Rhinorrhea (n = 133)     | 28 (21.1)           | 21 (23.1)                            | 7 (10.1)                          |
| Nausea/vomiting (n = 133)| 34 (25.6)           | 23 (25.3)                            | 11 (15.9)                         |
| Diarrhea (n = 138)       | 52 (37.7)           | 27 (29.7)                            | 25 (36.2)                         |
| Anosmia (n = 132)        | 18 (13.6)           | 15 (16.5)                            | 3 (4.3)                           |
| Hypogeusia (n = 131)     | 23 (17.6)           | 19 (20.9)                            | 4 (5.8)                           |
**Figure S1.** Diagram demonstrating the proportion of patients with antibody and viral load testing. SOT, solid-organ transplant.
Figure S2. Correlation between anti-RBD and anti-NP antibody levels at >14 days postdiagnosis. NP, nucleoprotein; RBD, receptor binding domain.

Spearman $\rho = 0.67$
$P < 0.0001$